title: Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts.
abstract: Previous studies have shown that human hemopoietic cells can be adoptively transferred into immunodeficient C.B-17 scid/scid (SCID) mice that lack autologous T and B lymphocytes, to generate chimeric animals. The future development of novel immunomodulatory drugs in transplantation will depend increasingly on experimental animal models to investigate the properties of the agents on human cells before starting clinical trials. However, in previous models of SCID mice engrafted with human PBLs, human T cells have been found either to be in an unresponsive state, unable to respond to mitogenic stimulations in vitro, or to mediate skin graft rejection only when HLA-primed in vivo before their adoptive transfer into SCID mice. In addition, T cells and other leukocyte subsets engraft quite poorly in the lymphoid tissues of the animals. In an attempt to develop a useful model for transplantation research, we have inoculated SCID mice with fresh human splenocytes from cadaveric organ donors (hu-Spl-SCID mice). In this model, various leukocyte subsets engraft effectively in different lymphoid compartments. In addition, human T cells retain their proliferative responses to mitogens and to alloantigens when tested 3 wk after engraftment into SCID mice. Finally, mice engrafted with unprimed human spleen cells acutely reject human foreskin allografts. Treatment of hu-Spl-SCID mice with OKT3, an immunosuppressive mAb directed against the human CD3 complex associated with the TCR, prevents the rejection of most human skin allografts, indicating a major role for human T cells in this phenomenon. Thus, this hu-Spl-SCID model may be useful for the study of immunosuppressive therapies in a preclinical in vivo setting.
authors.affiliation: Ben May Institute, Department of Pathology, Pritzker School of Medicine, University of Chicago, IL 60637.
authors.forename: M L
authors.initials: ML
authors.lastname: Alegre
authors.forename: L J
authors.initials: LJ
authors.lastname: Peterson
authors.forename: D R
authors.initials: DR
authors.lastname: Jeyarajah
authors.forename: M
authors.initials: M
authors.lastname: Weiser
authors.forename: J A
authors.initials: JA
authors.lastname: Bluestone
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000276:immunology; D005434:Flow Cytometry; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D016513:Mice, SCID / Q000276:immunology*; D016038:Skin Transplantation / Q000276:immunology; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD